From In Silico to In Vivo: Why Development Strategy Now Determines AI-Era Success

In this article, AustinPx CSO Dave Miller examines how artificial intelligence (AI) is reshaping the front end of drug discovery while exposing a growing gap between faster candidate generation and real-world developability. As AI helps researchers design increasingly complex molecules, formulation, stability, manufacturability, and scale-up challenges still determine whether those candidates can become viable medicines. Miller explores why early development strategy matters more than ever, and how feedback-driven formulation approaches can help teams move from digital promise to clinical reality. The article highlights why competitive advantage will depend not just on discovering better molecules, but on delivering them in forms that can be reliably manufactured and scaled.